A carregar...
Pioglitazone and cardiovascular risk reduction: time for a second look?
Insulin resistance, a fundamental pathophysiological abnormality in patients with type 2 diabetes, is associated with increased cardiovascular (CV) disease risk. In diabetes management, the macrovascular impact of antihyperglycemic agents that do not improve insulin sensitivity has generally been di...
Na minha lista:
| Publicado no: | Cardiovasc Endocrinol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Wolters Kluwer Health
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6768516/ https://ncbi.nlm.nih.gov/pubmed/31646121 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/XCE.0000000000000110 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|